




FIG. 1

Subject ID	CAR-T (cell/ul) Cmax	Day 28	Day 42	Day 56	Day 78	Day 100
L28US10003011	13805	7135	5279	5957	2836	2464
L28US10025003	6416	4639	1426	ND	798	1172
L28US10017023	5523	1736	1437	926	772	576
L28US10024005	4320	827	378	328	238	184
L28US10007001	4053	ND	894	828	615	533
L28US10002034	4024	844	454	1277	ND	1077
L28US10007002	3092	1767	1242	733	675	ND
L28US10002024	2890	249	383	514	316	ND
L28US10002023	2876	1826	1145	600	ND	562
L28US10001016	2846	2614	2382	2534	ND	1994
L28US10002032	1636	1146	595	610	ND	100
L28US10021007	1428	586	248	ND	ND	303

FIG. 2




FIG. 3






FIG. 4

**FIG. 5**

**FIG. 6**







FIG. 7

**FIG. 8A**

**FIG. 8B**

**FIG. 8B (continued)**





FIG. 9

*FIG. 9 (continued)*

Listing of Tumor Burden and Bridging Therapy; Subjects With Movement and Neurocognitive TEAEs; All Treated Analysis Set (Study 68284528MMY2001)					
Subject ID	Measurable Disease Type at Baseline	Clinical Tumor Burden Assessment at Baseline	SPD of EMP at Baseline if Present (mm ³)	Change in Tumor Burden from Screening to Cilia-Cel Infusion (%)	Bridging Therapy
L28US10002023	Serum only	Low	2348	-60	BORTEZOMIB, MELPHALAN
L28US10003011	Serum only	High	.	Not evaluable	CARFILZOMIB, DEXAMETHASONE
L28US10017023	Serum only	High	.	50	DEXAMETHASONE
L28US10021005	Serum only	Intermediate	.	14.3	DEXAMETHASONE
L28US10025003	FLC	High	.	50.1	DARATUMUMAB, DEXAMETHASONE, POMALIDOMIDE

Key: EMP = extramedullary plasmacytoma, SPD = sum of product diameters.
Note: High burden consists of subjects meeting any of the conditions: bone marrow plasma cell ≥30%, serum M-spike ≥5g/dL, serum free light chains ≥5000 mg/L. Low burden consists of subjects meeting all conditions available: bone marrow plasma cell <50%, serum M-spike <3g/dL, serum free light chains <3000 mg/L. Intermediate burden includes subject not meeting High nor Low burden criteria.
Note: Disease burden represents the type of measurable disease at enrollment: serum M-protein, urine M-protein, or difference between involved and uninvolved free light chain (dFLC).
Note: Tumor burden at JNJ-68284528 infusion is based on the last non-missing value on or prior to the date of JNJ-68284528 infusion and after apheresis.
Note: For subjects with measurable disease by serum M-protein and urine M-protein, the worst case scenario of change in tumor burden is presented i.e. the largest increase in tumor burden for subjects observed with increased tumor burden and the smallest decrease in tumor burden for subjects observed with decreased tumor burden.

FIG. 10




FIG. 11

Listing of Movement and Neurocognitive Treatment-Emergent Adverse Events; All Treated Analysis Set (Study 68284538MMY2001)										
Site ID	Subject ID	Age (years)/ Sex/Race	Line of Prior Therapy/ Year Since Diagnosis/ IES Staging at Study Baseline/ SPO of EMP at baseline if present (mm)	Worst Toxicity Grade of CRS/ICONS	Preferred Term/ Requested Term	Study Day of AE Onset/SAE Duration (days)	Toxicity Grade of Other Neurotoxicity/ SAE	Outcome	Relationship to Study 682845 28	Medication/Procedure Given (Start - End Day of Medication/Procedure)
US10012	128US10 062023	68/65/White	6/3/5/2344	3	Extrapyramidal/ BRADYKINESIA	1015	5N	Not Recovered/ Not Resolved	Poss	
					Micrographia/ MICROGRAPHIA	1017	5N	Not Recovered/ Not Resolved	VL	
					Parkinsonian/ PARKINSONIAN LINE SYNDROME	1015	1Y	Not Recovered/ Not Resolved	VL	PLASMAPHERESIS (105 - 106)
					Reduced facial expression/ HYPOMIMIA	1015	1N	Not Recovered/ Not Resolved	Poss	
					Stoodykinase/ BRADYKINESIA	1051	2N	Not Recovered/ Not Resolved	Poss	
					Parkinsonian/ PARKINSONIAN LINE SYNDROME	1051	2Y	Not Recovered/ Not Resolved	VL	ANAKINRA [121 - 126]; ANAKINRA [127 - 137]; CARBOPALAEYDOPHA [138 - 137]; ANAKINRA [137 - 137]; CARBOPALAEYDOPHA [141 - 147]; IMMUNOGLOBULIN HUMAN NORMAL [147 - 153]; CYCLOPHOSPHAMIDE [149 - 149]; CYTARABINE [149 - 149] [149]; CYCLOPHOSPHAMIDE [155 - 156]; CYTARABINE [156 - 156]; HYDROCORTISONE [156 - 156]
					Reduced facial expression/ HYPOMIMIA	1051	2N	Not Recovered/ Not Resolved	Poss	

FIG. 12

Listing of Movement and Neurocognitive Treatment-Emergent Adverse Events; All Treated Analysis Set (Study 66284528NMV2001)										
Site ID	Subject ID	Age (years)/ Sex/Race	Line of Prior Therapy/ Year Since Diagnosis/ ISG Staging at Study/ Baseline T present (mm)	Worst Toxicity Grade of CRS/CANS	Preferred Term/ Reported Term	Study Day of AE Onset/AE Duration (days)	Toxicity Grade of Other Neurotoxicities/SAE	Outcome	Relationship to JNJ-56284528	Medication/Procedure Given (Start - End Day of Medication/Procedure)
US10003	L29US1000011	58M/White	2/1.2/10	2/1	Decreased level of consciousness/ MENTAL FOG/ENSE	14	1N	Recovered/ Not Resolved	Poss	
					Parkinsonism/ PARKINSONISM	43/53	2N	Not Recovered/ Not Resolved	Poss	
					Tremor RIGID/ RIGID TREMOR	43	1N	Not Recovered/ Not Resolved	Poss	
					Flat affect/ FLAT AFFECT	100	2N	Not Recovered/ Not Resolved	Poss	
					Memory impairment/ DIFFICULTY WITH SHORT TERM MEMORY	100	2N	Not Recovered/ Not Resolved	Poss	
					Mental status changes/ ALTERED MENTAL STATUS	100/148	3P	Not Recovered/ Not Resolved	Poss	DEXAMETHASONE [116 - 118] / DEXAMETHASONE [117 - 120] / DEXAMETHASONE [120 - 121] / DEXAMETHASONE [122 - 123] / DEXAMETHASONE [123 - 129] / DEXAMETHASONE [130 - 134] / DEXAMETHASONE [135 - 137] / DEXAMETHASONE [138 - 140] / CYCLOPHOSPHAMIDE [144 - 146]
					Oral disturbance/ ORAL PRURITUS	105	2N	Not Recovered/ Not Resolved	Poss	

FIG. 12 (continued)

Listing of Movement and Neurocognitive Treatment-Emergent Adverse Events: All Treated Analysis Set (Study 58284528MMY2061)											
Site ID	Subject ID	Age (years): Sex/Race	Line of Prior Therapy: Year Since Diagnosis/ ISE Staging at Study Baseline, if present (month)	Worst Toxicity Grade of CRS/ICANS	Preferred Term/ Reported Term	Study Day of AE Onset/AE Duration (days)	Toxicity Grade of Other Neurotoxicities/SAE	Outcome	Results ship to JJJ-582845 28-	Medication/Procedure Given (Start - End Day of Medication/Procedure)	
					Micromedesis/ MICROGRAPHIA	105	2H	Not Recovered/ Not Resolved	Pass		
					Parkinsonism/ PARKINSONISM	105	3N	Not Recovered/ Not Resolved	Pass		
					Tremor/ LEFT HAND TREMOR	105	1H	Not Recovered/ Not Resolved	Pass		
US16017	LNUG510 017623	68/M/White	4-6.58	2H	Personality change/ PERSONALITY CHANGE	100-5	3N	Recovered/ Resolved	VL	ALPRAZOLAM [108 - 109] / ALPRAZOLAM [109 - 110]	
					Mood status changes/ ALTERED MENTATION	110-8	5Y	Recovering/ Resolving	VL	DEXAMETHASONE [110 - 113] / DEXAMETHASONE [113 - 115] / DEXAMETHASONE [115 - 118]	
					Confusional state/ INTERMITTENT CONFUSION	139-23	3Y	Recovered/ Resolved	Pass	HYDROCHLOROTHIONE [135 - 136] / METHOTREXATE [136 - 137] / CYCLOPHOSPHAMIDE [137 - 138]	

FIG. 12 (continued)

Listing of Movement and Neurocognitive Treatment-Emergent Adverse Events; All Treated Analysis Set (Study 88284528NNY2201)										
Site ID	Subject ID	Age (years)/ Sex/Face	Last of Prior Therapy/ Year Since Diagnosis/ US Staging at Study Baseline/ SPD of EMP at Baseline if present (prior)	Worst Toxicity Grade of CRS/ICARS	Preferred Term/ Reported Term Synonym(s) NABP/ITC TO WRITE	Study Day of AE Onset/AE Duration (days) 130/235	Faculty Grade of Other Neurotoxicities at Site 3/4	Outcome Resolved	Relationship to JNJ-61284528 Poss	Medication/Procedure Given (Start - End Day of Medication/Procedure)
										DEXAMETHASONE [132 - 138] / METHOTREXATE [135 - 139] / CYCLOPHOSPHAMIDE [138 - 139] / DEXAMETHASONE [138 - 143] / DEXAMETHASONE [141 - 143] / DEXAMETHASONE [144 - 147] / DEXAMETHASONE [148 - 149] / DEXAMETHASONE [150 - 160] / DEXAMETHASONE [171 - 173] / DEXAMETHASONE [173 - 175] / DEXAMETHASONE [175 - 183] / DEXAMETHASONE [180 - 184] / DEXAMETHASONE [184 - 189] / DEXAMETHASONE [188 - 187] / DEXAMETHASONE [188 - 190] / DEXAMETHASONE [190 - 197] / DEXAMETHASONE [197 - 202] / DEXAMETHASONE [204 - 214] / DEXAMETHASONE [212 - 218]

FIG. 12 (continued)

Listing of Movement and Neurocognitive Treatment-Emergent Adverse Events; All Treated Analysis Set (Study 882845288MY2001)										
Site ID	Subject ID	Age (years)/Sex/Race	Line of Prior Therapy/ Prior Event Diagnosis/ ISCT Staging of Study Baseline/SPC of EIMP at baseline/Pre-treatment (mm)	Worst Toxicity Grade of CRS/CRA/AS	Predetermined Term/ Reported Term	Study Day of AE Onset/AE Duration (days)	Toxicity Grade of Other Neurocognitive AE	Outcome	Relationship to Study Drug	Medication/Procedure Given (Start - End Day of Medication/Procedure)
					Motor dysfunction/ WEAK GRASP	150/288	3N	Recovered/ Resolved	Yes	DEXAMETHASONE [131 - 131] / DEXAMETHASONE [132 - 138] / METHOTREXATE [135 - 135] / CYCLOPHOSPHAMIDE [136 - 136] / DEXAMETHASONE [138 - 141] / DEXAMETHASONE [141 - 143] / DEXAMETHASONE [144 - 147] / DEXAMETHASONE [148 - 148] / DEXAMETHASONE [150 - 168] / DEXAMETHASONE [168 - 171] / DEXAMETHASONE [171 - 173] / DEXAMETHASONE [173 - 175] / DEXAMETHASONE [176 - 180] / DEXAMETHASONE [180 - 184] / DEXAMETHASONE [184 - 188] / DEXAMETHASONE [188 - 187] / DEXAMETHASONE [187 - 187] / DEXAMETHASONE [188 - 188] / DEXAMETHASONE [188 - 187] / DEXAMETHASONE [187 - 203] / DEXAMETHASONE [203 - 211] / DEXAMETHASONE [212 - 218]
					Personality change/ PERSONALITY CHANGES	182/17	3N	Recovered/ Resolved	VL	DEXAMETHASONE [132 - 138] / DEXAMETHASONE [138 - 141] / DEXAMETHASONE [141 - 143]

FIG. 12 (continued)

Listing of Movement and Neurocognitive Treatment-Emergent Adverse Events; All Treated Analysis Set (Study 68284528MMY2001)										
Site ID	Subject ID	Age (years)/ Sex/Race	Line of Prior Therapy/ Year Since Diagnosis/ ISS Staging at Study Baseline/ SPD at EMP at baseline & present (mm/s)	Worst Toxicity Grade of ONSET/CAUS	Preferred Term/ Reported Term	Study Day of AE Onset/AE Duration (days)	Toxicity Grade of Other Neurotoxicities/SAE	Outcome	Relationship to JNJ-68284528	Medication/Procedure Given (Start - End Day of Medication/Procedure)
					Personality change/ PERSONALITY CHANGES	1584	3N	Recovered/ Resolved	YL	DEXAMETHASONE [168 - 171]
					Stereotypy/ REPETITIVE MOVEMENTS	1682	3N	Recovered/ Resolved	VL	DEXAMETHASONE [168 - 171]
US18024	128UG10 921965	77M/White	19/5 NW	2+1	Tremor/ BILATERAL HAND TREMOR	27/95	5N	Recovered/ Resolved	Poss	
					Carpal tunnel rigidity/ UPPER EXTREMITIES	29/16	2N	Recovering/ Resolving	Poss	
					Parkinsonism/ PARKINSONIAN FEATURES	29/29	3Y	Recovering/ Resolving	Poss	
					Bradykinesia/ BRADYKINETIC	43/93	5N	Recovered/ Resolved	Poss	
					Carpal tunnel rigidity/ UPPER EXTREMITIES	43/96	5N	Recovered/ Resolved	Poss	
					Gait disturbance/ GAIT SLOWED	43/	5N	Not Recovered/ Not Resolved	Poss	
					Micrographia/ MICROGRAPHIA	48/93	5N	Recovered/ Resolved	Poss	
					Posture abnormal/ STOOPED POSTURE	43/146	5N	Not Recovered/ Not Resolved	Poss	
					Psychomotor retardation/ SLOW PSYCHOMOTOR FUNCTION	43/	5N	Not Recovered/ Not Resolved	Poss	

FIG. 12 (continued)

Listing of Movement and Neurocognitive Treatment-Emergent Adverse Events; All Treated Analysis Set (Study 68284528MMY2001)										
Site ID	Subject ID	Age (years)/ Sex/Race	Line of Prior Therapy/ Year Since Diagnosis/ ISE Staging at Study Baseline/ SPD of EMP at baseline if present (mm)	Worst Toxicity Grade of CRSICANS	Preferred Term/ Reported Term	Study Day of AE Onset/AE Duration (days)	Toxicity Grade of Other Neurotoxicity as SAE	Outcome	Relationship to Study 68284528	Medication/Procedure Given (Start - End Day of Medication/Procedure)
					Parkinsonian/ PARKINSONIAN FEATURES	56	1/Y	Not Recovered/ Not Resolved	Poss	
					Posture abnormal/ STICKED POSTURE	36/5	1/N	Not Recovered/ Not Resolved	Poss	
					Reduced facial expressions/ MASKLIKE FACE	36/5	1/N	Not Recovered/ Not Resolved	Poss	
US10025	L281513 / 025003	62/M/White	9/7.3/0	2/Y	Micrographia/ MICROGRAPHIA	12/15	1/N	Not Recovered/ Not Resolved	VL	
					Parkinsonian/ NERVOUS SYSTEM DISORDERS OTHER - PARKINSON'S DISEASE SYNDROME	18/12	1/N	Recovered/ Resolved With Sequelae	Poss	DEXAMETHASONE [22 - 30] / OXYGEN [72 - 110]
					Micrographia/ MICROGRAPHIA WORSEN	30	2/N	Not Recovered/ Not Resolved	VL	

FIG. 12 (continued)

Listing of Movement and Neurocognitive Treatment-Emergent Adverse Events, All Treated Analysis Set (Study 682643288M1Y2001)										
Site ID	Subject ID	Age (years/ Sex/Race)	Line of Prior Therapy/ Year Since Diagnosis/ ISS Staging at Study Baseline/ SPD of EMP at Baseline if present (prior)	Worst Toxicity Grade of CRS/ICANS	Preferred Term/ Reported Term	Study Day of AE Onset/AE Duration (days)	Toxicity Grade of Other Neurotoxic eae/AE	Outcome	Relation to JNJ-60264328	Medication/Procedures Given: Start - End Day of Medication/Procedures
					Parkinsonism/ NERVOUS SYSTEM DISORDER- OTHER PARKINSONS LIKE SYNDROME	33	3Y	Not Recovered/ Not Resolved	Prob	DEXAMETHASONE (22 - 30) / DEXAMETHASONE (30 - 47) / CARBOPOL/LEVODOPA (37 - 102) / DEXAMETHASONE (48 - 52) / CYCLOPHOSPHAMIDE (52 - 53) / DEXAMETHASONE (52 - 53) / CYTARABINE (53 - 55) / HYDROCORTISONE (55 - 56) / DEXAMETHASONE (56 - 57) / GILTUXIMAB (57 - 57) / DEXAMETHASONE (57 - 58) / DEXAMETHASONE (58 - 61) / HYDROCORTISONE (61 - 61) / METHYLPREDNISONE (61 - 61) / DEXAMETHASONE (61 - 102) / LEVETIRACETAM (64 - 64) / LEVETIRACETAM (64 - 64) / DASATINIB (65 - 67) / DASATINIB (73 - 76) / ANAKINRA (76 - 82) / DASATINIB (76 - 107) / ANAKINRA (86 - 102)
					Reduced facial expressions/ MASKED FACES	33	1Y	Not Recovered/ Not Resolved	Prob	
					Memory impairment/ MEMORY IMPAIRMENT	37	4Y	Not Recovered/ Not Resolved	Prob	

FIG. 12 (continued)

Listing of Movement and Neurocognitive Treatment-Emergent Adverse Events: All Treated Analysis Set (Study 682643288MY2301)										
Site ID	Subject ID	Age (years)/ Sex/Race	Line of Prior Therapy/ Year Since Diagnosis/ ISL: Staging at Study Baseline/ EPS of EAP at baseline: if present (yes?)	Worst Toxicity Grade of CRS/CANS	Preferred Term/ Reported Term	Study Day of AE Onset/AE Duration (days)	Toxicity Grade of Other Neurotoxicity/ SAE	Outcome	Relationship to JNJ-68264328	Medication/Procedure Given [Start - End Day of Medication/Procedure]
Key: AE = adverse event, CRS = cytokine release syndrome, DO = duration, EAP = extramedullary plasmacytoma, ICARIS = Immune Effector Cell-Associated Neurotoxicity, NR = not related, Poss = possible, Prob = probable, SAE = serious adverse event, EPS = sum of product of diameters, VL = very likely * Study day of AE onset is in reference to the initial administration of JNJ-68264328 (Day 1). * Relationship to JNJ-68264328 is assessed by the investigator. Note: Adverse events are coded using MedDRA Version 25.0.										

FIG. 12 (continued)






FIG. 13

**FIG. 14**

**FIG. 15**